Avalyn Pharma Inc.
Clinical trials sponsored by Avalyn Pharma Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New inhaled therapy aims to slow lung scarring in IPF Results expected Dec 2026 (estimated)
- New inhaled therapy aims to slow lung scarring in progressive fibrosis Results expected Jun 2027 (estimated)
-
New inhaled drug for lung scarring moves to Long-Term safety check
Disease control Recruiting nowThis study looks at the long-term safety of an inhaled drug (AP01) for people with progressive lung scarring (pulmonary fibrosis). It is for those who already completed an earlier Avalyn Pharma study. About 340 participants will receive the drug and be monitored for side effects …
Phase 2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New inhaled therapy aims to slow lung scarring in IPF
Disease control Recruiting nowThis study tests an inhaled version of the drug nintedanib (called AP02) in people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 160 adults aged 40 and older who are not currently on IPF treatment will take either a low o…
Phase 2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC